Shravan Kandula, MD

home / authors / shravan-kandula-md

Articles

A panel of 3 experts on nasopharyngeal carcinoma

Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

Barbara Burtness, MD;Victoria M. Villaflor, MD;Shravan Kandula, MD

September 11th 2024

The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.

Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

Barbara Burtness, MD;Victoria M. Villaflor, MD;Shravan Kandula, MD

September 11th 2024

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

Barbara Burtness, MD;Victoria M. Villaflor, MD;Shravan Kandula, MD

September 4th 2024

Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.

Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

Barbara Burtness, MD;Victoria M. Villaflor, MD;Shravan Kandula, MD

September 4th 2024

Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.

Value of PD-L1 Biomarker in NPC

Barbara Burtness, MD;Victoria M. Villaflor, MD;Shravan Kandula, MD

August 28th 2024

A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.

Overview of the JUPITER and POLARIS-2 Trials

Barbara Burtness, MD;Victoria M. Villaflor, MD;Shravan Kandula, MD

August 28th 2024

Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.

Current Guidelines for Managing Nasopharyngeal Carcinoma

Barbara Burtness, MD;Victoria M. Villaflor, MD;Shravan Kandula, MD

August 21st 2024

Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.

Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

Barbara Burtness, MD;Victoria M. Villaflor, MD;Shravan Kandula, MD

August 21st 2024

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.